Technology

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Published

3 hours ago

June 11, 2026

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven’s common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley and Barclays are acting as joint book-running managers for the proposed offering. Mizuho is also acting as a book-running manager and LifeSci Capital is acting as a passive book-running manager for the proposed offering.

The offering is being made pursuant to a Registration Statement on Form S-3ASR, including a base prospectus, which became automatically effective upon filing with the U.S. Securities and Exchange Commission (SEC) on August 13, 2025, and Enliven will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which can be accessed for free through the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Enliven within the meaning of the federal securities laws, including those related to the completion, timing, and size of the offering and Enliven’s intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not Enliven will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Enliven files from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the public offering. These forward-looking statements are made as of the date of this press release, and Enliven assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302798527.html

SOURCE Enliven Therapeutics, Inc.

Technology

SmartOrg releases Version 10.x of its Decision Intelligence platform

Published

13 minutes ago

June 11, 2026

New release expands SmartOrg’s Decision Intelligence platform with a cleaner, more configurable experience and new product capabilities.

PALO ALTO, Calif., June 11, 2026 /PRNewswire-PRWeb/ — SmartOrg, Inc., a Palo Alto-based provider of Decision Intelligence solutions, today announced the release of version 10.x of its software platform, with its standard products Innovation Navigator® and Portfolio Navigator® now deployed by configuring modules on a newly integrated platform.

“This release is really about giving customers a better experience and more flexibility in how they apply the platform to their specific decision challenges.”

Combined in other ways, these modules support deployments optimized for other contexts.

“This release is really about giving customers a better experience and more flexibility in how they apply the platform to their specific decision challenges,” said David Matheson, President and CEO of SmartOrg. “We’re delighted to see customers using SmartOrg’s Decision Intelligence Platform in more targeted ways, for example in Technology Assessment, Energy Exploration and Drug Discovery. Version 10.x gives them a cleaner, more configurable foundation for doing that work.”

The release includes major updates to Innovation Navigator®, including flexible brainstorming canvases, enhanced Learning Plan modules, and upgraded Discovery Grid visualizations. These enhancements help innovation teams capture ideas, organize learning activities, and focus attention on the uncertainties that matter most.

Portfolio Navigator® also receives significant new capabilities, including a Maturity Matrix, Probability of Success calculator, and portfolio goal analysis. These features help leaders better assess projects, compare them, and support portfolio decisions.

“Version 10.x is part of our ongoing commitment to keeping SmartOrg’s software current, useful, and easier for customers to apply,” said Dave Wachenschwanz, Director of Development at SmartOrg. “The platform has significant upgrades in its user interface, improving consistency and usability.”

To see highlights of the new release, SmartOrg has published a short video overview from its development team that you can watch here: https://bit.ly/4xdA7QY

About SmartOrg

SmartOrg helps innovation, R&D, and strategy teams convert uncertainty to opportunity. Its software products—Innovation Navigator® and Portfolio Navigator®—apply quantitative methods to prioritize learning, build confidence in the business case, and guide investment decisions at both the project and portfolio levels to help organizations meet their growth objectives.

Media Contact

Doug Williams, SmartOrg, Inc., 1 3399270834, dwilliams@smartorg.com, https://smartorg.com

View original content to download multimedia:https://www.prweb.com/releases/smartorg-releases-version-10x-of-its-decision-intelligence-platform-302796404.html

SOURCE SmartOrg, Inc.

Technology

Cathay Financial Holdings Leverages Open-Source Small Language Models to Identify Customer Intent

Published

14 minutes ago

June 11, 2026

Fine-tuning Small Language Models to Better Understand Local Financial Service Contexts, Domain Terminology, and Ambiguous Customer Queries

TAIPEI, June 12, 2026 /PRNewswire/ — To enhance operational efficiency and customer experience, Cathay Financial Holdings (Cathay FHC) continues to advance the application of generative AI in financial services through its generative AI technical framework, GAIA, and AI-as-a-Service (AIaaS) strategy. Building on last year’s validation of large language models (LLMs) for financial applications, Cathay FHC recently unveiled its latest AI research findings at NVIDIA GTC Taipei 2026, demonstrating how open-source small language models (SLMs) can be fine-tuned for customer intent classification and applied to future financial service scenarios.

The study evaluated several leading open-source models from Meta, TAIDE, TAME, NVIDIA and OpenAI. Preliminary results showed that, under the testing framework, fine-tuned SLMs may reduce dependence on complex prompt engineering and vector retrieval modules, potentially simplifying system architecture while lowering future operational and maintenance complexity.

The findings indicated that, when combined with carefully designed financial-domain datasets and targeted model fine-tuning, SLMs can further improve model stability, inference efficiency, and deployment controllability. In customer intent classification, the fine-tuned SLM achieved performance close to mainstream closed-source LLMs, approaching that of leading proprietary LLMs, providing enterprises with a practical reference for evaluating AI model training and deployment strategies.

From a data governance and privacy perspective, the study adopted a fully synthetic data approach, ensuring that no real customer information was used during model training. Through techniques including service-function clustering, single-intent and multi-intent dataset design, Taiwan-context localization, and keyword expansion, Cathay FHC strengthened the model’s ability to understand local financial service contexts, industry-specific terminology, and ambiguous customer queries.

Potential future applications include mortgage balance inquiries, credit card payment assistance, and branch service navigation, laying the groundwork for intelligent search, service routing, and next-generation customer engagement experiences.

From a technical architecture standpoint, Cathay FHC integrated NVIDIA AI tools—including NVIDIA NeMo Customizer, NVIDIA NeMo Curator, and NVIDIA TensorRT-LLM—together with NVIDIA Hopper architecture computing resources to support data generation, model fine-tuning, inference optimization, and experimental evaluation. Leveraging NVIDIA AI ecosystem, Cathay FHC continues to strengthen its capabilities in financial-domain model development, data governance, and application validation.

In recent years, Cathay FHC has steadily expanded AI innovation across a wide range of financial scenarios, building scalable technological foundations spanning internal process optimization, customer service enhancement, financial knowledge understanding, and model governance. As financial institutions navigate an increasingly regulated environment, stringent data governance requirements, and rapidly evolving customer expectations, Cathay FHC remains committed to advancing AI research in a compliant, secure, and resilient manner.

Looking ahead, Cathay FHC will continue exploring long-context classification, advanced financial document understanding, and cross-scenario AI applications. By developing model training and deployment approaches tailored to the financial sector, the company aims to accelerate innovation and create more intelligent, efficient, and customer-centric financial services.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cathay-financial-holdings-leverages-open-source-small-language-models-to-identify-customer-intent-302798631.html

SOURCE Cathay Financial Holdings

Technology

First Advantage Set to Join S&P SmallCap 600

Published

14 minutes ago

June 11, 2026

NEW YORK, June 11, 2026 /PRNewswire/ — First Advantage Corporation (NASD: FA) will replace Kennedy-Wilson Holdings Inc. (NYSE: KW) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, June 16. A consortium led by KW’s CEO with Fairfax Financial Holdings Limited (TSE: FFH) is acquiring Kennedy-Wilson Holdings in a deal expected to close soon, pending final closing conditions.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name

Action

Company Name

Ticker

GICS Sector

June 16, 2026

S&P SmallCap 600

Addition

First Advantage

Industrials

June 16, 2026

S&P SmallCap 600

Deletion

Kennedy-Wilson Holdings

Real Estate

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/first-advantage-set-to-join-sp-smallcap-600-302798639.html

SOURCE S&P Dow Jones Indices